Kinetics of ^99mTc-Labelled Antibodies against CD₄ (T-Helper) Lymphocytes in Man

Zusammenfassung

Die Verfügbarkeit ^99mTc-markierter CD₄-Antikörper erlaubt das Studium ihres kinetischen Verhaltens bei rheumatischen Patienten. Prospektiv wurden Patienten mit rheumatoider Arthritis untersucht. Drei dieser Patienten erhielten 250 µg eines mit 555 MBq ^99mTc markierten CD₄-Antikörpers (MAX16H5) injiziert. Ein Patient erhielt in vitro mit ^99mTc markierte Lymphozyten. 4% der Aktivität wurden renal eliminiert. Von 4 nach 24 h p. i. fiel der Milzuptake von 7,5 auf 4%, der Leberuptake stieg von 25 auf 30%, der Knochemarkuptake blieb vergleichbar (50%), während der Uptake über einem großen erkrankten Gelenk von 2 geringfügig auf 2,5% stieg. 15 bis 30 min nach der Antikörperinjektion war eine Umverteilung von Aktivität zu registrieren, die einer Lymphozytenredistribution vergleichbar war. Die Recoveryrate (0-1 h) der in vivo markierten Zellen betrug 30%, die der in vitro markierten Zellen 19%. Ein Patient wurde mit in vitro CD₄-Antikörper-markierten Lymphozyten untersucht. Ein signifikanter Unterschied der Kinetik beider Präparationen war nicht zu registrieren. Zusammenfassend schließen die Autoren, daß zirkulierende CD₄-exprimierende Lymphozyten mit CD₄-Antikörpern markiert werden können. Die kinetischen Daten erinnern an jene rezirkulierender Lymphozyten.

Summary

The availability of radiolabeled anti-CD₄ antibodies permitted the study of their kinetic behaviour. Four patients suffering from rheumatoid arthritis were investigated prospectively. Three of them received 250 µg of ^99mTc-labelled anti-CD₄ antibody (MAX.16H5). One patient received in vitro ^99mTc-antibody-labelled lymphocytes. 4% of the activity was excreted by the kidneys. From 4 to 24 h the splenic uptake decreased from 7.5 to 4%, the liver uptake increased from 25 to 30% the bone marrow uptake remained about the same 50% and the uptake of a single diseased joint (2%) increased slightly to 2.5%. 15 to 30 min after injection of the antibody a redistribution of labelled cells or antibody from liver and spleen to the circulating blood seemed to occur. The recovery rate (0-1 h) of in vivo labelled cells amounted to 30%, that of in vitro labelled cells to 19%. One patient was examined with in vitro labelled CD₄-expressing lymphocytes. There was no difference in the antibody kinetics between in vitro and in vivo labelled cells. The authors suggest that circulating CD₄-lymphocytes can be labelled with monoclonal antibodies. The kinetics of these in vitro labelled cells and the injected labelled antibody itself resembles that of recirculating lymphocytes.Patients and Methods

Schlüsselwörter

^99mTc - CD₄-Antikörperimmunszintigraphie - kinetisches Verhalten

Key words

Immunoscintigraphy - ^99mTc-labelled antibodies - CD₄-(T-lymphocyte) antibodies - cell kinetics

• REFERENCES

• 1 Becker W, Borst U, Fischbach W. et al. Kinetic data of in-vivo labeled granulocytes in humans with a murine ^99mTc labeled monoclonal antibody. Eur J Nucl Med 1989; 15: 361-6.
• 2 Becker W, Emmrich F, Horneff G. et al. Imaging autoimmune rheumatoid arthritis specifically with ^99mTc-labelled anti-CD ₄ (T-helper lymphocytes) antibodies. Eur J Nucl Med 1990; 17: 156-9.
• 3 Becker W, Schomann E, Fischbach W, Börner W, Grüner KR. Comparison of ^99mTc-HMPAO and ¹¹¹In-oxin labeled granulocytes in man - first clinical results. Nucl Med Commun 1988; 09: 435-47.
• 4 Boyum A. Separation of leukocytes from blood and bone marrow. Scand J Clin Lab Invest 1968; 21 (Suppl. 97) 77.
• 5 Bull BS, Westengard JC, Farr M. et al. Efficacy of tests used to monitor rheumatoid arthritis. Lancet 1989; ii: 965-7.
• 6 Burmester GR, Kalden JR, Peter HH. et al. Immunological and functional characteristics of peripheral blood and synovial fluid lymphocytes from patients with rheumatoid arthritis. Scand J Immunol 1987; 07: 405.
• 7 Carrasquillo JA, Bunn PA, Keenan AM. et al. Radioimmunodetection of cutaneous T-cell lymphoma with ¹¹¹In labeled T-101 monoclonal antibody. N Engl J Med 1986; 315: 673-80.
• 8 Chisholm PM, Danpure HJ, Healey G, Osmann S. Cell damage from the labeling of rat thoracic duct lymphocytes and HeLa 53 cells with Indium-111 oxin. J Nucl Med 1979; 20: 1308-11.
• 9 Doly M, Chassagne J, Demeocq F. et al. Labelling of human lymphocytes with ^99mTc by means of stannous pyrophosphate. Scientific applications. Eur J Nucl Med 1982; 07: 397-404.
• 10 Emmrich F. Empfehlungen für die Herstellung und Prüfung in vivo applizierbarer monoklonaler Antikörper. Dtsch Med Wschr 1987; 112: 194-8.
• 11 Emmrich F. Activation of T cells by crosslinking the T cell receptor complex with the differentiation antigens CD₄ and CD₈. Implications for the generation of MHC-restriction and for repertoire selection in the thymus. Immunology Today 1988; 09: 296-300.
• 12 Emmrich F, Eichmann K, Weltzien HU. The generation of the repertoire of T cell specificities and functions: towards a consistent model. Progr in Immunol VI. Toronto: 1986: 406-17.
• 13 Fisher B, Packard BS, Read EJ. et al. Tumor localisation of adoptively indium-111 labeled tumor infiltrating lymphocytes in patients with metastatic melanoma. J Clin Oncol 1989; 07: 250-61.
• 14 Gobuty A, Robinson RG, Barth RF. Organ distribution of ^99mTc- and ⁵¹Cr labeled autologous peripheral blood lymphocytes in rabbits. J Nucl Med 1977; 08: 141-6.
• 15 Hamilton D, Cowan RA, Sharma HL. et al. The behaviour of autologous ^111mIn-labeled lymphocytes in patients with lymphoid cell malignancy. J Nucl Med 1988; 29: 485-93.
• 16 Herzog Ch, Walker Ch, Pichler W. et al. Monoclonal anti-CD₄ in arthritis. Lancet 1987; ii: 1461-2.
• 17 Horneff G, Burmester GR, Strobel G. et al. Therapie der chronischen Polyarthritis mit einem monoklonalen Antikörper gegen das CD₄-Antigen auf T-Helferzellen. Akt Rheumatol 1989; 14: 232.
• 18 Horneff G, Burmester GR, Emmrich F, Kalden JR. Treatment of rheumatoid arthritis with an anti-CD₄ monoclonal antibody. Arthritis Rheum. (in press).
• 19 Janossy G, Panay G, Duke O. et al. Rheumatoid arthritis: a disease of T-lymphocyte/ macrophage immunoregulation. Lancet 1981; ii: 839-42.
• 20 Kissmeyer-Nielsen F. ed. Tissue: histocompatibility and immunogenetics. Kopenhagen: Munsgaard; 1989: 63.
• 21 Lavender JP, Goldman JM, Arnot RN, Thakur ML. Kinetics of indium-111-labeled lymphocytes in normal objects and patients with Hodgkin’s disease. Br Med J 1977; 02: 797-99.
• 22 Moebius U. Cluster report CD₄. White cell differentiation antigens leukocyte typing. IV. Oxford University Press; Oxford, New York, Tokyo: 1989: 314-46.
• 23 McCarty J, Hollander JI. eds. Arthritis and allied conditions. A textbook of rheumatology. Philadelphia: Lea & Febiger; 1985: 77-8.
• 24 Milgram R, Goodwin D. Human scanning with ¹¹¹In-oxine labeled autologous lymphocytes. Clin Nucl Med 1985; 10: 30-4.
• 25 Rannie GH, Bell EB. Lymphocyte traffic within the bone marrow and selective retention of alloreactive cells. Transplantation 1979; 27: 369-74.
• 26 Rankin EM, Hekman A, Hardeman MR, Hoefnagel CA. Dynamic studies of lymphocytes labeled with ¹¹¹In during and after treatment with monoclonal antiidiotype antibody in advanced B cell lymphoma. Br Med J 1984; 289: 1097-100.
• 27 Saverymuttu SH, Peters AM, Danpure HJ. et al. Lung transit of indium-111 labelled granulocytes. Scand J Hematol 1983; 30: 151-60.
• 28 Schwarz A, Steinsträßer A. A novel approach to ⁹⁹Tc-labelled monoclonal antibodies. J Nucl Med 1987; 28: 721.
• 29 Szer IS, Irani A, Burmester GR, Winchester RJ. Four new surface antigens on T lymphocytes. Leukocyte Typing. Springer; Berlin, Heidelberg, New York: 1981: 718.
• 30 Wagstaff J, Gibson C, Thatcher N. et al. Human lymphocytic traffic assessed by indium-111 oxine labelling: clinical observation. Clin Exp Immunol 1981; 43: 443-9.
• 31 Wagstaff J, Gibson C, Thatcher N. et al. A method for following human lymphocyte traffic using ¹¹¹in oxine labelling. Clin Exp Immunol 1981; 43: 435-42.